CYTK
NASDAQ
US
Cytokinetics, Incorporated - Common Stock
$66.73
▲ +$0.12
(+0.18%)
Vol 2.5M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$7.8B
ROE
-131.2%
Margin
-862.2%
D/E
600.92
Beta
0.49
52W
$29–$71
Wall Street Consensus
26 analysts · Apr 20265
Strong Buy
17
Buy
4
Hold
0
Sell
0
Strong Sell
84.6%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.49 | $-1.50 | $-0.01 |
| Sep 2025 | $-1.61 | $-2.55 | $-0.94 |
| Jun 2025 | $-1.41 | $-1.12 | +$0.29 |
| Mar 2025 | $-1.41 | $-1.39 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $16.9M | $1.6M | $66.8M | $1.9M | $17.8M |
| Net Income | -$150.0M | -$161.4M | -$134.4M | -$306.2M | -$183.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -132.0% | -132.0% | -132.0% | -131.2% | -131.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -201.3% | -707.2% | -707.2% | -707.2% | -862.2% | -862.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 603.36 | 603.36 | 603.36 | 600.92 | 600.92 |
| Current Ratio | 6.76 | 6.76 | 6.76 | 6.76 | 6.88 | 6.88 |
Key Ratios
ROA (TTM)
-56.5%
P/S (TTM)
89.08
P/B
15.7
EPS (TTM)
$-6.31
CF/Share
$-5.44
Rev Growth 3Y
-36.0%
52W High
$70.98
52W Low
$29.31
$29.31
52-Week Range
$70.98
Financial Health
Free Cash Flow
-$148.3M
Net Debt
$1.2B
Cash
$122.5M
Total Debt
$1.3B
As of Dec 31, 2025
How does CYTK compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CYTK valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
89.1
▲
593%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
15.7
▲
538%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CYTK profitability vs Biotechnology peers
ROE
-131.2%
▼
95%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-862.2%
▼
201%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-56.5%
▼
21%
below
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CYTK financial health vs Biotechnology peers
D/E ratio
600.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
6.9
▲
55%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.5
▼
49%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CYTK fundamentals radar
CYTK
Peer median
Industry
CYTK profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CYTK vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
CALLOS ANDREW
Officer · Mar 18
1930 shs
MALIK FADY IBRAHAM
Officer · Mar 17
12033 shs
BLUM ROBERT I
Chief Executive Officer · Mar 17
36601 shs
LEE SUNG
Chief Financial Officer · Mar 17
4935 shs
CALLOS ANDREW
Officer · Mar 17
8542 shs
CALLOS ANDREW
Officer · Mar 16
1709 shs
MALIK FADY IBRAHAM
Officer · Mar 13
27306 shs
HESSEKIEL JEFFREY J
Officer · Mar 13
20646 shs
LEE SUNG
Chief Financial Officer · Mar 13
20646 shs
CALLOS ANDREW
Officer · Mar 13
33966 shs
Last 90 days
Top Holders
Top 5: 54.31%T. Rowe Price Investment Ma…
14.38%
$1.1B
Blackrock Inc.
13.31%
$1.0B
FMR, LLC
10.40%
$800.5M
Vanguard Group Inc
9.78%
$753.0M
Wellington Management Group…
6.44%
$496.1M
As of Dec 31, 2025
Latest News
No related news yet